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Abstract
Background: Endocrine therapy is commonly recommended in the adjuvant setting for patients as treatment for ductal
carcinoma in situ (DCIS). However, it is unknown whether a neoadjuvant (preoperative) anti-estrogen approach to DCIS
results in any biological change. This study was undertaken to investigate the pathologic and biomarker changes in DCIS
following neoadjuvant endocrine therapy compared to a group of patients who did not undergo preoperative anti-
estrogenic treatment to determine whether such treatment results in detectable histologic alterations.
Methods: Patients (n = 23) diagnosed with ER-positive pure DCIS by stereotactic core biopsy were enrolled in a trial
of neoadjuvant anti-estrogen therapy followed by definitive excision. Patients on hormone replacement therapy, with
palpable masses, or with histologic or clinical suspicion of invasion were excluded. Premenopausal women were treated
with tamoxifen and postmenopausal women were treated with letrozole. Pathologic markers of proliferation,
inflammation, and apoptosis were evaluated at baseline and at three months.
Biomarker changes were compared to a cohort of patients who had not received preoperative treatment.
Results:  Median age of the cohort was 53 years (range 38–78); 14 were premenopausal. Following treatment,
predominant morphologic changes included increased multinucleated histiocytes and degenerated cells, decreased duct
extension, and prominent periductal fibrosis. Two postmenopausal patients had ADH only with no residual DCIS at
excision. Postmenopausal women on letrozole had significant reduction of PR, and Ki67 as well as increase in CD68-
positive cells. For premenopausal women on tamoxifen treatment, the only significant change was increase in CD68. No
change in cleaved caspase 3 was found. Two patients had invasive cancer at surgery.
Conclusion: Preoperative therapy for DCIS is associated with significant pathologic alterations. These changes may be
clinically significant. Further work is needed to identify which women may be the best candidates for such treatment for
DCIS, and whether best responders may safely avoid surgical intervention.
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Background
Ductal carcinoma in situ (DCIS) was diagnosed in over
60,000 women in the United States in 2008[1]. The inci-
dence of DCIS has risen almost 5-fold over the last 15
years, and now represents 25–30% of all mammographi-
cally detected breast cancers[2,3]. Moreover, studies sug-
gest that the undetected disease reservoir of DCIS could be
even larger. Autopsy series in women dying of causes
other than breast cancer show that over 10% of whole
breast specimens may harbor DCIS not previously recog-
nized [4-6]. Since DCIS is rarely palpable, mammography
is the primary mode of detection. As mammographic
screening has become more sensitive and widespread,
more clinically occult preinvasive disease continues to be
detected.
The current treatment of DCIS is based on a presumption
that DCIS is a non-obligate precursor of invasive breast
cancer. There is a paucity of natural history studies since
DCIS is generally surgically resected upon diagnosis. The
few retrospective reports of women who had biopsies that
were assumed to be benign but on later review were found
to have DCIS report a 20–50% risk of invasive cancer in
the twenty years after biopsy [7-12]. Without validated
measures with which to stratify future risk for invasive
cancer, the current goal of all DCIS treatment is preven-
tion of cancer progression through surgery, radiation, hor-
monal therapy, or a combination of these modalities[7].
In fact, despite the 99% survival rate from DCIS, these
aggressive treatments are not much different than those
recommended for the invasive cancers these interventions
are aimed to prevent. Thus, current therapy for DCIS may
represent overtreatment for many women who may never
progress to invasive cancer. Nevertheless, expectant man-
agement alone is not currently considered an acceptable
alternative for most women, due to fear of invasive pro-
gression.
In prospective randomized trials, adjuvant tamoxifen and
aromatase inhibitor (AI) have both been associated with
significantly reduced risk of contralateral invasive breast
cancer [13-16]. One possible explanation for this observa-
tion is that endocrine therapy may prevent progression of
in situ to invasive disease. If indeed the risk of DCIS pro-
gression could be reduced with primary medical therapy
alone, some women with DCIS could potentially avoid
the morbidity of surgery and radiation as well as derive
benefit from contralateral risk reduction. Tamoxifen is
already offered as adjuvant treatment for DCIS, based on
data from a prospective placebo-controlled trial in
women undergoing lumpectomy and radiation showing a
benefit in DFS which favored tamoxifen[14]. Ongoing
clinical trials are studying the role of AI in both the pre-
vention and adjuvant settings for DCIS. However, the bio-
logic impact of endocrine therapy directly on DCIS
lesions themselves remains largely unexplored.
To our knowledge, this is the first report examining the
biologic changes that accompany preoperative endocrine
treatment of ER-positive pure DCIS. Our aim was to deter-
mine whether a 3-month course of preoperative endo-
crine therapy for DCIS could result in measurable
histologic and immunohistochemical changes when com-
pared to baseline assessments made on initial diagnostic
core biopsy. To reduce possible systematic bias in immu-
nohistochemistry (IHC) scoring arising from differences
in tissue fixation of core biopsy versus surgical excision
specimens, we also performed a matched analysis of IHC
changes on core biopsy compared to surgical excision on
controls who did not undergo preoperative treatment.
Methods
Treated Cases
Patients treated at the University of California San Fran-
cisco Comprehensive Cancer Center between 2003 and
2007 were offered participation in an investigator-initi-
ated clinical trial studying the effect of preoperative endo-
crine therapy in DCIS. The study was reviewed and
approved by the UCSF IRB in compliance with the Hel-
sinki Declaration (CHR approval H10367-19435), and
written informed consent from all participants was docu-
mented. Patients diagnosed with pure DCIS by stereotac-
tic core needle biopsy of microcalcifications were
recruited to a trial of 3 months of neoadjuvant endocrine
therapy. Patients with current hormone replacement use,
palpable masses, hormone receptor-negative DCIS, or
clinical suspicion of invasion were excluded from study
participation.
Premenopausal patients were treated with tamoxifen (20
mg PO QD), while postmenopausal patients were treated
with letrozole (2.5 mg PO QD). Definitive excision con-
sisting of either lumpectomy or mastectomy was planned
per study protocol at the completion of three months of
preoperative therapy.
Untreated Controls
Patients undergoing surgery for DCIS at our institution
between 2003 and 2006 who consented to have tissue
banked for research were identified. Those with invasive
cancer and those for whom diagnostic core biopsy blocks
or surgical blocks were not available were excluded. Eight-
een consecutive cases were evaluable for all biomarkers
assessed.
Histopathology and Biomarker Assessment
Hematoxylin and eosin (H&E)-stained sections from all
pre-treatment and post-treatment biopsies were reviewedBMC Cancer 2009, 9:285 http://www.biomedcentral.com/1471-2407/9/285
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by the study pathologist (YC). Diagnosis was rendered
according to the criteria established by Page et al[17] and
the WHO classification system[18]. Grading was based on
the evaluation of cytonuclear features and divided into
three grades (1 to 3). Other features of DCIS were also
recorded including architectural pattern, presence and
type of necrosis, microcalcifications, associated foamy
macrophages and multinucleated giant cells.
Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded tissue sections using the strepta-
vidin-biotin peroxidase method. Antibodies and dilutions
used were: ER (DAKO, Carpinteria, CA) at 1:400 dilution;
PR (Novocastra) at 1:25; HER2 (Zymed) at 1:200; Ki-67
(DAKO) at 1:100; CD68 (DAKO) at 1:100; and cleaved
caspase 3 (Cell Signaling, Beverly, MA) at 1:200.
Antigen retrieval was achieved using either heat-induced
epitope retrieval in 10 mM citrate buffer at pH 6.0 (for ER,
PR, CD68, and caspase 3), incubation with Ficin (Zymed)
at 37°C (for HER2), or 0.01% trypsin digestion followed
by heat treatment in 10 mM citrate buffer (for Ki-67).
Slides were blocked in 3% H2O2 and then incubated with
the primary antibodies. HER2  gene amplification was
determined by FISH analysis using the PathVysion HER2
DNA Probe Kit (Vysis Inc., Downer's Grove, IL) according
to manufacturer recommendations.
In order to minimize the impact of IHC staining variabil-
ity in the analysis, specific care was taken to ensure that
matched pretreatment and postreatment specimens were
stained in the same run.
Scoring of Biomarkers
All immunostains were evaluated by two pathologists (YC
and RS) and scored randomly so that pre- and post-treat-
ment samples were evaluated independently for both
cases and controls. The scoring was perfomed without
knowledge of other immunostains from the same speci-
men. Pathologists were also blinded to the scoring of the
paired pre- or post-treatment sample.
ER and PR were scored by evaluating the percentage and
intensity of stained tumor nuclei (H-score) as previously
described[19,20]. Staining intensity ranged from 0 to 3+,
with 0 representing no staining, 1+ weak staining, 2+
moderate staining, and 3+ strong staining. Percentages of
positive tumor cells in each staining intensity category
were recorded. Results of ER and PR were expressed as the
H-score where: H-score = (1 × %1+) + (2 × %2+) + (3 ×
%3+).
HER2 was scored by criteria established by the HercepTest
(DAKO), using a 0–3 scale, based on staining intensity of
tumor cells. Staining intensities 0 and 1 were considered
negative; intensity 2 indeterminate, and intensity 3 posi-
tive for HER2 protein overexpression. FISH analysis was
performed on all cases with staining intensity 2–3 by
immunohistochemistry, and cases showing a ratio of
HER2:centromere 17 copy number greater than 2.0 were
considered positive for gene amplification.
Ki-67 staining was used to establish a proliferation index.
Slides were first scanned at low-power magnification to
select DCIS foci with highest mitotic activity. Where pos-
sible, at least 500 tumor cells were counted in these mitot-
ically active areas. Proliferation index was obtained by the
percentage of tumor nuclei that were labeled by Ki-67.
CD68 staining was used to identify DCIS infiltrating mac-
rophages. Macrophage density was recorded by scanning
at low-power magnification to choose DCIS foci with
highest concentration of CD68 positive cells. The number
of intraductal CD68 positive macrophages was counted in
three high-power fields (hpf, 400×). The macrophage
density was expressed as the mean number of macro-
phages per hpf.
Cleaved caspase 3 staining was used to evaluate activation
of apoptosis, and was interpreted as positive in tumor
cells with strong granular staining in the cell. Where pos-
sible, a minimum of 500 tumor cells was scored in each
sample. Only predominantly intact cells were counted.
The results were expressed as the percentage of tumor cells
expressing cleaved caspase 3.
Statistics
A non-parametric rank-sum test for non-normalized dis-
tribution of data was used to compare changes in IHC
markers between cases and controls, as well as between
baseline and treated cases. Significance was established at
a p value of < 0.05.
Results
Patient Characteristics
From 2003 to 2007, 23 patients completed the study pro-
tocol with both pre- and post-treatment materials availa-
ble for analysis. Overall, the treatment was well tolerated.
One patient (H-24) was discontinued from the study; she
was taken off tamoxifen on day 31 due to an arterial
embolic event.
Two premenopausal patients declined excision and chose
to continue the endocrine treatment. However, follow-up
post-treatment core needle biopsies were performed on
these two patients and were compared to pre-treatment
samples. The remaining patients underwent definitive
surgical excision following preoperative endocrine ther-BMC Cancer 2009, 9:285 http://www.biomedcentral.com/1471-2407/9/285
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apy. Table 1 and Additional File 1http://wald
man.ucsf.edu/Waldman.Primary.Data.html summarize
the clinical characteristics of the study population.
Pathologic Features
The baseline pre-treatment core biopsies showed a range
of DCIS nuclear grade with 12/23 patients diagnosed with
non-high grade disease (Table 1). Comparison of tumor
grade between pre- and post-treatment specimens showed
that the nuclear grade remained the same in 14 cases,
changed to lower grade in five, and became higher grade
in two cases (Table 2; Additional File 2: http://wald
man.ucsf.edu/Waldman.Primary.Data.html).
Extent of surgery was guided by mammographic extent of
calcifications. In two patients, post-treatment surgical
specimens demonstrated atypical ductal hyperplasia
(ADH) only. These patients had residual mammographi-
cally visible calcifications following core biopsy, with cal-
cifications confirmed pathologically on the post-
treatment surgical specimen, but no DCIS was seen asso-
ciated with microcalcifications following treatment.
DCIS was identified in 21 patients following endocrine
treatment. Morphologically, the post-treatment samples
were less distended and demonstrated increased periduc-
tal fibrosis and inflammation when compared to the pre-
treatment biopsies (Figures 1a, 1b). Treated samples also
had more pronounced multinucleated histiocytes and
degenerated cells within DCIS and ADH. In addition to
multinucleated histiocytes and degenerated cells, the
ADH in post-treatment samples demonstrated microcalci-
fications similar to those noted in the pre-treatment DCIS
or adjacent post-treatment DCIS, suggesting some of the
ADH could represent treated DCIS but with a lesser degree
Table 1: Characteristics of Study Population
Cases
Controls Postmenopausal Premenopausal
N1 8 9 1 4
Age at diagnosis (y) 54 61 46
DCIS grade
low 2 0 1
intermediate 7 5 6
high 9 4 7
Type of surgery
lumpectomy 16 8 7
mastectomy 2 1 5
none 0 0 2
Table 2: Comparison of histologic diagnosis at baseline and following neoadjuvant anti-estrogenic therapy
ID Age at diagnosis Menopausal status Baseline diagnosis1 Post-treatment diagnosis
H-02 56 post G2-3 DCIS, LCIS G2 DCIS, G2 IDC (1.2 cm), LCIS
H-042 41 pre G2-3 DCIS G2-3 DCIS
H-07 48 pre G2 DCIS G2 DCIS
H-14 65 post G1-2 DCIS ADH
H-15 49 pre G2 DCIS G1-2 DCIS, ADH
H-162 60 post G2 DCIS G3 DCIS, G2 IDC (1.8 cm)
H-17 45 pre G1 DCIS, ADH, FEA G1 DCIS, ADH, FEA
H-18 53 pre G3 DCIS G3 DCIS
H-19 47 pre G2 DCIS, ADH G1 DCIS
H-20 55 post G1-2 DCIS G2 DCIS
H-21 52 pre G2 DCIS G2 DCIS
H-22 65 post G1-2 DCIS G1 DCIS, ADH
H-23 44 post G2 DCIS G1 DCIS
H-24 42 pre G2 DCIS, FEA G2-3 DCIS, FEA
H-27 43 pre G2-3 DCIS G2 DCIS
H-29 52 post G3 DCIS ADH
H-302 78 post G3 DCIS G3 DCIS
H-312 52 post G2-3 DCIS G2-3 DCIS
H-33 41 pre G2-3 DCIS G2-3 DCIS
H-34 42 pre G2 DCIS G1-2 DCIS
H-35 68 post G3 DCIS G3 DCIS
H-36 44 pre G2-3 DCIS G2-3 DCIS
H-382 46 pre G2-3 DCIS G2-3 DCIS
1abbreviation: G: grade; DCIS: ductal carcinoma in situ; IDC: invasive ductal carcinoma; LCIS: lobular carcinoma in situ; ADH: atypical ductal 
hyperplasia; FEA: flat epithelial hyperplasia.
2Her2 IHC 3+BMC Cancer 2009, 9:285 http://www.biomedcentral.com/1471-2407/9/285
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of cytoarchitectural features for diagnosis of DCIS. Two
postmenopausal patients were also found to have inter-
mediate grade, ER-positive invasive ductal carcinoma,
measuring 1.2 and 1.8 cm respectively.
Biomarker Expression
The range of IHC staining for ER, Ki67, CD68, and caspase
3 for all three grades of DCIS is illustrated in Additional
File 3. Changes in DCIS IHC expression from baseline to
treated specimens are summarized in Table 3. The magni-
tude of change in treated cases and untreated controls
were compared.
ER
Hormone treatment resulted in a reduction of ER expres-
sion as demonstrated by the ER H-score. Although there
was downregulation of ER expression, all DCIS lesions
remained ER-positive. Reduction of ER staining was mod-
est in the majority of the patients but at least 50% in 9 of
23 patients. This reduction was most pronounced among
the postmenopausal women treated with letrozole, where
it approached statistical significance.
PR
Endocrine treatment resulted in a marked reduction in PR
expression. Three cases completely lost PR staining after
treatment (H-score = 0) while all the other cases remained
PR-positive. Nine of 23 cases had at least 50% downregu-
lation in percentage of tumor cells staining positive for
PR. This reduction in PR expression was significant among
all cases, but stratified analysis showed that the reduction
in PR was limited to the postmenopausal group treated
with letrozole.
Ki-67
A significant reduction in Ki-67 labeling index was
observed after endocrine therapy among both pre- and
post-menopausal patients (Figures 1c, 1d). This change
was significant when compared to untreated controls.
DCIS nuclear grade was correlated with mean pre-treat-
ment Ki67 (grade 1: 7.7%; grade 2: 17.4%; grade 3:
23.5%), although this finding was not statistically signifi-
cant (p = 0.09). Notably, grade 3 DCIS showed the great-
est mean reduction of Ki67 with treatment (13.3%),
compared to grade 1 and grade 2 DCIS (6.5% and 6.1%
respectively). The mean reduction in Ki-67 in postmeno-
pausal cases was greater than that observed in premeno-
pausal cases (Figures 2a, 2b).
Macrophage density
Analysis of macrophage density by CD68 showed that
endocrine therapy was associated with a significant
increase of macrophages within the lesional ducts com-
pared to controls (Table 3; Figures 2c, 2d). All except two
cases demonstrated an increase in macrophage density in
post-treatment specimens. The change in macrophage
density was correlated with the morphologic findings of
many foamy macrophages and multinucleated giant cells
identified in the post-treatment samples (Figures 1e, 1f).
HER2-neu
Of the 23 cases, five showed both HER2 protein overex-
pression (staining intensity 3 on immunohistochemistry)
and/or HER2 gene amplification (HER2 gene to centro-
mere 17 ratio > 2). Neoadjuvant endocrine therapy did
not alter the HER2 status in any of the DCIS lesions. Inter-
estingly, the reduction in Ki-67 did not differ significantly
between HER2-positive and HER2-negative cases.
Cleaved caspase 3
There was no significant treatment effect on apoptosis as
measured by the cleaved caspase 3 assay. Among those
treated with endocrine therapy, twelve cases showed
increased expression of cleaved caspase 3, although these
changes were of small magnitude (mean change 0.1,
range -6.5 to 6).
Histology of baseline (A, C, E) and endocrine-treated (B, D,  F) DCIS from patient H-20 (magnification: 100×) Figure 1
Histology of baseline (A, C, E) and endocrine-treated 
(B, D, F) DCIS from patient H-20 (magnification: 
100×). A, B: H&E stain of baseline (A) and treated (B) sam-
ples. The treated DCIS is less distended and demonstrates 
increased periductal sclerosis and inflammation compared to 
baseline. C, D: Ki67; reduction in Ki-67 after treatment com-
pared to baseline; E, F: CD68 (inset: 400×); increased CD68-
positive macrophages after treatment compared to baseline.BMC Cancer 2009, 9:285 http://www.biomedcentral.com/1471-2407/9/285
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Discussion
The aim of our study was to determine the effects of pre-
operative endocrine therapy on morphology and biomar-
ker expression in DCIS. We found that administration of
anti-estrogenic treatment for DCIS resulted in marked
morphologic changes, decreased proliferation, and pro-
tein expression changes. Changes were compared to con-
trols who did not undergo preoperative treatment,
confirming that our findings were associated with inter-
vening therapy rather than differences in tissue fixation
between core biopsy and surgical specimens. Endocrine
therapy also increased macrophage density within DCIS
ducts. However, a significant change in apoptosis as meas-
ured by cleaved caspase 3 was not observed, suggesting
that apoptosis was not significantly affected by this short
course of treatment.
Clinical trials of neaodjuvant endocrine therapy in estro-
gen-positive invasive breast cancer have demonstrated a
clear clinical objective response of at least 35% for both
tamoxifen and aromatase inhibitors at 3 or 4 months [21-
23]. If hormone therapy also induces regression in DCIS,
alterations in morphology of DCIS would have been
expected. In the present study, most cases treated with
neoadjuvant therapy showed morphologic changes in the
DCIS. These included a decrease in duct distention, an
increase in periductal sclerosis and scattered degenerated
cells, as well as an increase in macrophage infiltrate. These
morphologic changes are compatible with treatment
effect and may represent regression of DCIS. Furthermore,
two of the 23 cases treated with endocrine therapy dem-
onstrated only ADH without residual DCIS in the post-
treatment excision specimens. We cannot entirely exclude
the possibility that all DCIS was removed during the ini-
tial core biopsy for these two patients. However, the ADH
seen in the post-treatment specimens was present imme-
diately adjacent to biopsy site changes, demonstrated sim-
ilar microcalcifications as those observed in the original
DCIS, and showed similar cytologic features but less
developed architecture as in the corresponding pre-treat-
ment DCIS. Furthermore, degenerating epithelial cells
and multinucleated giant cells were noted within the ADH
ducts. Therefore, the morphologic features of these post-
treatment ADH suggest that they may represent altered
DCIS associated with treatment.
The anti-tumor effect of targeted endocrine therapy could
be attributed to decreased proliferation and/or increased
apoptosis at the cellular level. In this study, neoadjuvant
endocrine therapy reduced cellular proliferation in DCIS
cells, as measured by reduction in Ki-67. Our findings are
in agreement with data reported by Boland et al. which
showed a significant reduction in the percentage of prolif-
erating cells in ER-positive DCIS following estrogen with-
drawal[24]. Previous studies have also demonstrated an
antiproliferative effect of tamoxifen and aromatase inhib-
itors in invasive breast cancer [25-31]. Most recently, in a
study evaluating the DCIS component in prospective ran-
domized window trial of letrozole versus anastrozole for
ER-positive postmenopausal invasive cancer, a significant
drop in Ki67 was seen for both groups in the DCIS com-
ponent of the tumor[32]. In aggregate, these studies con-
firm that endocrine therapy effectively reduces
proliferation in DCIS.
However, endocrine therapy did not have a discernible
effect on apoptosis as measured by the cleaved caspase 3
assay. The lack of an observed apoptotic effect could be
due to the limited sample size, or other apoptotic path-
ways not detected by the caspase 3 assay. Alternatively the
drug concentrations at the DCIS site after oral tamoxifen
or letrozole may have been below the levels required for
activation of such programmed cell death pathways. Pre-
vious studies have shown conflicting results on the associ-
ation between endocrine treatment and apoptosis. While
in vitro[33,34], animal model[35] and one clinical[36]
study demonstrated activation of apoptosis by endocrine
therapy, other clinical trials on invasive breast cancer
failed to show increased apoptosis by tamoxifen,
raloxifene, or letrozole[31,37,38]. Further studies are
Table 3: Change in biomarkers with anti-estrogenic treatment
Controls (n = 18) All Cases (n = 23) Postmenopausal Cases (n = 9) Premenopausal Cases (n = 14)
Biomarker Mean change1 Mean change p2 Mean change p Mean change p
ER (H-score)3 -55.5 ± 22.2 -92.1 ± 23.7 0.21 -113.8 ± 26.2 0.07 -78.2 ± 35.4 0.62
PR (H-score)3 -38.8 ± 18.3 -110.1 ± 18.7 0.03 -169.2 ± 18.8 0.001 -72.1 ± 22.0 0.40
Ki-674 -3.2 ± 1.7 -10.2 ± 1.8 0.007 -14.4 ± 3.6 0.013 -7.5 ± 1.6 0.037
CD684 -0.06 ± 1.7 34.1 ± 8.3 <0.0001 29.4 ± 5.8 <0.0001 37.2 ± 13.2 0.002
caspase 35 0.8 ± 0.7 0.1 ± 0.4 0.15 -0.1 ± 0.7 0.13 0.2 ± 0.5 0.33
1Data shows mean increase (positive values) or mean decrease (negative values) in quantitative immunohistochemical staining between diagnostic 
core biopsy and surgical excision. Cases were treated with neoadjuvant anti-estrogenic therapy; controls did not undergo neoadjuvant therapy.
2Rank-sum test, controls as referent group.
3H-score is weighted measure of intensity and percentage of positive cells (see Methods).
4Percent of cells staining positive.
5Number of CD68-positive macrophages per high power field within DCIS ducts.BMC Cancer 2009, 9:285 http://www.biomedcentral.com/1471-2407/9/285
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required to elucidate the effect on apoptotic activity by
endocrine therapy in DCIS.
Short-term treatment with AI resulted in downregulation
of ER and PR expression in the DCIS cells, an effect not
seen with tamoxifen treatment. This is consistent with
studies in invasive breast cancer which also demonstrated
changes in ER and PR expression after endocrine ther-
apy[26,29-31,37,39]. The mechanism for ER downregula-
tion by endocrine therapy is unclear. A previous study
suggested that the effect was likely a post-transcriptional
modification as there was no change of ER mRNA
level[40]. On the other hand, the PR gene is an estrogen-
regulated gene, so drugs with endocrine activity would be
expected to reduce PR expression. Indeed, post-treatment
PR H-score of less than 10 was noted in four cases, all of
whom were treated with letrozole.
In this cohort, five cases overexpressed Her2. There was no
difference in Ki-67 reduction between Her2-positive and
Her2-negative cases in this small study. The IMPACT trial
which compared neoadjuvant tamoxifen to anastrozole in
ER-positive invasive breast cancer has suggested that when
compared to HER2-negative tumors, HER2-positive
lesions tended to show less antiproliferative effect follow-
ing endocrine treatment[27]. This effect may not have
been detectable in this small cohort. However, the neoad-
juvant therapy approach demonstrated in our study may
provide an ideal model for addressing the impact of HER2
overexpression on the response to hormone therapy in
DCIS in larger clinical trials.
Importantly, two of the 23 patients had invasive ductal
carcinoma in addition to DCIS in post-treatment excision
specimens. One of the invasive carcinomas was HER2-
positive, as was its associated DCIS. In both cases, the
invasive tumors were hormone receptor-positive. The
invasive carcinoma was likely present at initial diagnosis,
but the focus missed due to sampling error. The rate of
invasive cancer seen in our study is somewhat lower than
reported rates of upstaging to invasive cancer (20–25%)
in patients with DCIS only on core biopsy[41,42]. This
may reflect a higher degree scrutiny for invasive cancer for
those patients enrolling on this study, as assessed on both
clinical examination and radiographic work-up. Both
patients with invasive cancer underwent clinical examina-
tion, mammography, and MRI prior to study entry, none
of which were suspicious for invasive cancer. In the cur-
rent study, this would not have been expected to impact
patient outcome as all patients had ER-positive disease
and definitive surgery was performed in all but two
patients who declined surgery. Thus essentially, these
postmenopausal patients were treated with a standard
course of neoadjuvant aromatase inhibitor therapy. How-
ever, the risk of invasive disease not detected at stereotac-
tic core biopsy is an important consideration for future
trials of non-operative treatment for preinvasive disease,
and underscores the importance of patient selection in the
design of preoperative clinical trials in DCIS. Current
efforts, including some in our own group, are focusing on
efforts to improve discrimination of invasive cancer and
DCIS on MRI by optimizing both image acquisition and
software analysis technology to address this important
need.
Finally, it is important to note that any studies seeking to
evaluate non-surgical alternatives for what is currently a
surgically treated disease will encounter challenges in
study design, recruitment and analysis. Since DCIS is a
noninvasive condition, it presents an ideal opportunity to
study those patients at low risk of cancer progression, but
clinical trial designs must be take into account the risk for
invasive cancer, as discussed above, as well as patient
acceptance of new treatment approaches, and must
remain cognizant of the difficulties inherent in prospec-
tive randomization of patients between medical and sur-
gical treatment alternatives. Many of these barriers will be
overcome with greater patient and provider education.
Conclusion
In conclusion, preoperative hormone therapy for DCIS
was feasible and well tolerated, and the effect of neoadju-
vant hormone therapy in the setting of DCIS was associ-
ated with significant changes in both morphology and
biomarker expression. The reduction of proliferation con-
firms that systemically administered drug delivery to
intraductal lesions is sufficient to exert a favorable bio-
Changes in Ki67 labeling index (A, B) and CD68-positive  macrophage count (C, D) between baseline and treated  DCIS Figure 2
Changes in Ki67 labeling index (A, B) and CD68-posi-
tive macrophage count (C, D) between baseline and 
treated DCIS. There was significant reduction in Ki67 in 
premenopausal cases (p = 0.04) and in postmenopausal cases 
(p = 0.01). Similarly, CD68-positive macrophage density 
increased in both premenopausal (p = 0.002) and in post-
menopausal cases (p < 0.0001). Significance was determined 
by the rank-sum test comparing treated to baseline values.
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logic effect. Whether this effect is sufficient to prevent
invasive progression in the long-term is an important and
compelling subject for additional research. However, our
study opens the door for future trials evaluating the poten-
tial role of non-operative options for DCIS. The neoadju-
vant approach described in our study provides a
framework for evaluating the response of DCIS to preop-
erative therapies currently, including trials of agents tar-
geting ER-negative disease. Such studies will yield
important insight about the mechanisms involved in
breast cancer progression and will thus inform the design
of more targeted prevention studies. Although prelimi-
nary, our findings can initiate the dialogue for considera-
tion of primary hormone therapy alone for DCIS in a
select population of patients. As a follow-up to this cur-
rent study, we are planning a multi-center clinical trial
comparing longer intervals of letrozole treatment in post-
menopausal women with ER-positive DCIS to further
explore the acceptability, safety and efficacy of this
approach.
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